Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Serine/threonine-protein kinase PAK 1 | ||
Ligand | BDBM50148921 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_1584620 (CHEMBL3820948) | ||
Ki | 3.7±n/a nM | ||
Citation | Rudolph, J; Murray, LJ; Ndubaku, CO; O'Brien, T; Blackwood, E; Wang, W; Aliagas, I; Gazzard, L; Crawford, JJ; Drobnick, J; Lee, W; Zhao, X; Hoeflich, KP; Favor, DA; Dong, P; Zhang, H; Heise, CE; Oh, A; Ong, CC; La, H; Chakravarty, P; Chan, C; Jakubiak, D; Epler, J; Ramaswamy, S; Vega, R; Cain, G; Diaz, D; Zhong, Y Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window. J Med Chem59:5520-41 (2016) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
Serine/threonine-protein kinase PAK 1 | |||
Name: | Serine/threonine-protein kinase PAK 1 | ||
Synonyms: | 2.7.11.1 | Alpha-PAK | Cell division control protein 42 homolog | PAK 1/CDC42 | PAK-1 | PAK1 | PAK1_HUMAN | Serine/threonine-protein kinase PAK 1/PAK 2/PAK 3 | p21-activated kinase 1 | p65-PAK | ||
Type: | n/a | ||
Mol. Mass.: | 60640.15 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q13153 | ||
Residue: | 545 | ||
Sequence: |
| ||
BDBM50148921 | |||
n/a | |||
Name | BDBM50148921 | ||
Synonyms: | CHEMBL3770443 | ||
Type | Small organic molecule | ||
Emp. Form. | C25H25ClN6O3 | ||
Mol. Mass. | 492.957 | ||
SMILES | CNc1ncc2cc(-c3ccc(cc3Cl)-c3cccc(C)n3)c(=O)n(C[C@H]3OC[C@H](N)CO3)c2n1 |r,wU:26.27,wD:29.31,(-5.08,.92,;-4.02,1.54,;-2.68,.77,;-2.68,-.77,;-1.33,-1.54,;,-.77,;1.33,-1.54,;2.66,-.77,;4,-1.54,;3.99,-3.08,;5.33,-3.85,;6.66,-3.08,;6.66,-1.54,;5.33,-.77,;5.33,.46,;7.99,-3.86,;9.33,-3.09,;10.66,-3.86,;10.66,-5.4,;9.32,-6.17,;9.32,-7.4,;7.99,-5.4,;2.66,.77,;3.73,1.38,;1.33,1.54,;1.33,3.08,;2.67,3.85,;2.68,5.39,;4.01,6.15,;5.34,5.38,;6.41,5.99,;5.34,3.84,;4,3.07,;,.77,;-1.33,1.54,)| | ||
Structure |